Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07152002
PHASE1

A Study of LY4064912 in Healthy Participants and With Overweight or Obesity

Sponsor: Eli Lilly and Company

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate how well LY4064912 is tolerated and what side effects may occur in healthy participants and participants with overweight and obesity - global. The study drug will be administered either subcutaneously (SC) (under the skin) or infusion intravenously (IV) (into a vein in the arm). Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.

Official title: A Phase 1, Randomized, Placebo-Controlled, Single and Multiple Ascending Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY4064912 in Healthy Participants and Participants With Overweight or Obesity

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

144

Start Date

2025-08-28

Completion Date

2026-11

Last Updated

2026-03-03

Healthy Volunteers

Yes

Interventions

DRUG

LY4064912

Administered SC

DRUG

LY4064912

Administered IV

DRUG

Placebo

Administered SC

DRUG

Placebo

Administered IV

Locations (3)

Collaborative Neuroscience Network - CNS

Los Alamitos, California, United States

ICON Early Phase Services

San Antonio, Texas, United States

Lilly Centre for Clinical Pharmacology

Singapore, Singapore